Quantitative changes of melanoma-associated antigens as a biomarker for targeted therapy response

被引：1
|
作者：
Arenberger, Petr [1 ,2 ]
Fialova, Alena [1 ,2 ]
Gkalpakiotis, Spyridon [1 ,2 ]
Pavlikova, Andrea [3 ]
Arenbergerova, Monika [1 ,2 ]
机构：
[1] Charles Univ Prague, Dept Dermatovenereol, Fac Med 3, Srobarova 50, Prague 10034 10, Czech Republic
[2] Fac Hosp Kralovske Vinohrady, Srobarova 50, Prague 10034 10, Czech Republic
[3] Fac Hosp Kralovske Vinohrady, Inst Lab Diagnost, Prague, Czech Republic
来源：
EXPERIMENTAL DERMATOLOGY | 2016年 / 25卷 / 09期
关键词：
biomarker; circulating tumor cell; melanoma; targeted therapy; CIRCULATING TUMOR-CELLS; SURVIVAL; PCR;
D O I：
10.1111/exd.12947
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：727 / 729
页数：3
相关论文
共 50 条
  • [41] Identification of Age-Associated Transcriptomic Changes Linked to Immunotherapy Response in Primary Melanoma
    El-Helbawy, Nehal Farid
    El Zowalaty, Ahmed Ezat
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2022, 44 (09) : 4118 - 4131
  • [42] MHC ANTIGEN EXPRESSION BY MELANOMAS RECOVERED FROM MICE TREATED WITH ALLOGENEIC MOUSE FIBROBLASTS GENETICALLY-MODIFIED FOR INTERLEUKIN-2 SECRETION AND THE EXPRESSION OF MELANOMA-ASSOCIATED ANTIGENS
    KIM, TS
    COHEN, EP
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1994, 38 (03) : 185 - 193
  • [43] 18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence?
    van der Hiel, Bernies
    Blankenstein, Stephanie A.
    Aalbersberg, Else A.
    Wondergem, Maurits
    Stokkel, Marcel P. M.
    van de Wiel, Bart A.
    Klop, W. Martin C.
    van Akkooi, Alexander C. J.
    Haanen, John B.
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (07) : 583 - 589
  • [44] Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response
    Carey, Alexis E.
    Weeraratna, Ashani T.
    PHARMACOLOGY & THERAPEUTICS, 2024, 262
  • [45] Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study
    Khattak, Muhammad A.
    Abed, Afaf
    Reid, Anna L.
    McEvoy, Ashleigh C.
    Millward, Michael
    Ziman, Melanie
    Gray, Elin S.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [46] Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma
    Chen, Hualin
    Liu, Meilian
    Dai, Zhiwei
    Li, Shujun
    Luo, Yiping
    Wang, Yongcun
    Su, Wenmei
    Cai, Weijing
    Yang, Donghong
    Huang, Jian
    Yang, Zhixiong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1225 - 1234
  • [47] IMMUNIZATION OF MICE WITH ALLOGENEIC FIBROBLASTS GENETICALLY-MODIFIED FOR INTERLEUKIN-2-SECRETION AND EXPRESSION OF MELANOMA-ASSOCIATED ANTIGENS STIMULATE PREDETERMINED CLASSES OF ANTIMELANOMA EFFECTOR-CELLS
    KIM, TS
    COHEN, EP
    JOURNAL OF IMMUNOTHERAPY, 1994, 16 (01): : 24 - 35
  • [48] Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
    Di Guardo, Lorenza
    Randon, Giovanni
    Corti, Francesca
    Vallacchi, Viviana
    Raimondi, Alessandra
    Fuca, Giovanni
    Bini, Marta
    Maurichi, Andrea
    Patuzzo, Roberto
    Gallino, Gianfrancesco
    Mattavelli, Ilaria
    Ruggeri, Roberta
    Angi, Martina
    Cossa, Mara
    Valeri, Barbara
    Cimminiello, Carolina
    Santinami, Mario
    Rivoltini, Licia
    de Braud, Filippo
    Rodolfo, Monica
    Del Vecchio, Michele
    ONCOLOGIST, 2021, 26 (12) : 1079 - 1084
  • [49] Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report
    de Joode, Karlijn
    Veenbergen, Sharon
    Kransse, Claudia
    Kortleve, Dian
    Debets, Reno
    Mathijssen, Ron H. J.
    Joosse, Arjen
    Schreurs, Marco W. J.
    van der Veldt, Astrid A. M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [50] Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
    Schouwenburg, Maartje G.
    Suijkerbuijk, Karijn P. M.
    Koornstra, Rutger H. T.
    Jochems, Anouk
    van Zeijl, Michiel C. T.
    van den Eertwegh, Alfons J. M.
    Haanen, John B. A. G.
    Aarts, Maureen J. B.
    van Akkooi, Alexander C. J.
    van den Berkmortel, Franchette W. P. J.
    de Groot, Jan Willem B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Kruit, Wim H.
    Piersma, Djura
    van Rijn, Rozemarijn S.
    ten Tije, Albert J.
    Vreugdenhil, Gerard
    van der Hoeven, Jacobus J. M.
    Wouters, Michel W. J. M.
    CANCERS, 2019, 11 (12)
12345